Biogen Inc. (Nasdaq: BIIB) today announced a new virtual research study, in collaboration with Apple, to investigate the role Apple Watch and iPhone could play in monitoring cognitive performance and screening for decline in cognitive health including mild cognitive impairment (MCI). [Read more…] about The new frontier in neurocognitive monitoring and dementia screening: the Apple Watch
” … 19 individuals older than 65 years of age who were experiencing cognitive decline were randomized to a control group or an intervention group for 8 weeks. The control group received online information related to dementia and lifestyle risk factors, Mediterranean diet, physical activity, and cognitive engagement. Participants were instructed to implement this information into their own lifestyles. The intervention group received the same online information, plus active components to assist with implementing this information into their lifestyles: dietitian sessions, an exercise physiologist session, and online brain training. [Read more…] about Study: Actual, sustained practice–not mere knowledge–is needed to harness neuroplasticity and improve cognition over time
Common Class of Drugs Linked to Increased Risk of Alzheimer’s Disease (UC San Diego release):
A team of scientists, led by researchers at University of California San Diego School of Medicine, report that a class of drugs used for a broad array of conditions, from allergies and colds to hypertension and urinary incontinence, may be associated with an increased risk of cognitive decline, particularly in older adults at greater risk for Alzheimer’s disease (AD) … cognitively normal study participants who were taking at least one anticholinergic drug at baseline were 47 percent more likely to develop mild cognitive impairment (MCI), often a precursor to dementia such as AD, while being tracked over a period of up to a decade compared to participants who did not take such drugs. [Read more…] about Anticholinergic drugs found to significantly increase risk of cognitive decline, especially among those with Alzheimer’s Disease biomarkers or genetic predisposition
Apple, Eli Lilly research whether devices can detect dementia signs (Healthcare Dive):
“Dementia, which affects roughly 47 million people across the globe, costs $1 trillion worldwide, according to the World Health Organization. Early testing for the condition is sporadic and, when conducted, it’s often not sensitive enough to detect early stages of mental decline, creating an opportunity for tech companies like Apple to see whether they can turn a profit.
The “rich, longitudinal information” from wearable and mobile consumer devices can be [Read more…] about Apple/ Eli Lilly’s bet: Wearable and mobile consumer devices may well help us detect cognitive impairment and dementia
Practice Imperfect: Repeated Cognitive Testing Can Obscure Early Signs of Dementia (UC San Diego Health press release):
“Alzheimer’s disease (AD) is a progressive, neurodegenerative condition that often begins with mild cognitive impairment or MCI, making early and repeated assessments of cognitive change crucial to diagnosis and treatment.
But in a paper published online in the journal Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, a team of researchers led by scientists at the University of California San Diego School of Medicine found that repeated testing of middle-age men produced a “practice effect” which obscured true cognitive decline and [Read more…] about Study: Practice effect due to repeated testing can delay detection of cognitive impairment and dementia
“Computerized cognitive training (CCT) for patients with mild cognitive impairment (MCI) appears to have a beneficial effect on global cognition, memory, and attention and improves psychosocial functioning, including depressive symptoms, [Read more…] about Study: Computerized cognitive training may help patients with mild cognitive impairment (less so once diagnosed with dementia)